On April 3, 2023 Gossamer Bio, Inc. (the "Company") reported that the U.S. Food and Drug Administration (the "FDA") has placed a partial clinical hold on all trials of GB5121, in response to serious adverse events that have been observed in the Phase 1b/2 STAR-CNS study, including atrial fibrillation, a sudden death event and a fatal intracranial hemorrhage (Press release, Gossamer Bio, APR 3, 2023, View Source [SID1234631618]). The Company previously announced on March 17, 2023 that it had paused enrollment of the Phase 1b/2 STAR-CNS Study based on the benefit / risk profile observed to date and a prioritization of resources to support the Company’s seralutinib program. Based on the foregoing factors, the Company has decided to terminate all ongoing studies and discontinue development of GB5121.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!